Summary of Ovid Therapeutics Conference Call Company Overview - **Company**: Ovid Therapeutics (NasdaqGS:OVID) - **CEO**: Meg Alexander, who has been in the role for approximately two and a half months [1][5][11] Key Product: OV329 - **Mechanism of Action**: OV329 is designed to elevate endogenous levels of GABA, potentially serving as a significant anticonvulsant for epilepsy [15][19] - **Differentiation**: It represents a novel mechanism of action in a field that has seen only two new mechanisms in the last 20 years, addressing a critical need for new treatment options for patients resistant to current therapies [15][17] - **Tolerability**: Early data suggests OV329 may be better tolerated than existing seizure medications, with no drug-drug interactions and no need for titration [17][18] - **Development Status**: The company plans to initiate a randomized placebo-controlled Phase 2 study with a 7-milligram dose in Q2 2026, with results expected by mid-2026 [38][41][43] Clinical Data and Efficacy - **Preclinical and Clinical Data**: OV329 has shown promising preclinical results, including cortical inhibition in healthy volunteers, and elevated GABA levels consistent with its mechanism [34][35][37] - **Seizure Reduction Goals**: The company aims for a seizure reduction efficacy of 30-50% in focal onset seizures, emphasizing the importance of tolerability alongside efficacy [61][63] Competitive Landscape - **Market Positioning**: Ovid Therapeutics has strategically chosen to focus on differentiated mechanisms rather than competing in crowded areas with multiple similar drugs [64][67] - **Future Outlook**: The company believes there is potential for OV329 to become a significant player not only in focal onset seizures but also in pediatric epilepsies [67] Additional Product: KCC2 (OV4071) - **Mechanism**: KCC2 is a potassium chloride cotransporter that plays a crucial role in GABAergic signaling and is neuron-specific, reducing the risk of off-target effects [81][84] - **Therapeutic Potential**: The company sees KCC2 as a promising target with potential applications across various conditions, including psychoses and pain [85][135] - **Initial Indications**: The focus for OV4071 includes Parkinson's disease psychoses and schizophrenia, with plans to explore broader applications based on emerging data [135][136] Development Strategy - **Indication Selection**: Ovid Therapeutics is prioritizing indications based on mechanistic rationale and existing data, aiming to mitigate risks in clinical trials [138] - **Future Pipeline**: The company has multiple development candidates related to KCC2 that have not yet been publicly discussed, indicating a robust pipeline for future growth [149] Conclusion - Ovid Therapeutics is positioned to make significant advancements in the treatment of epilepsy and related disorders through its innovative products OV329 and OV4071, with a strong focus on tolerability and efficacy in a competitive landscape. The company is actively preparing for upcoming clinical trials and regulatory discussions to further its development goals.

Group 1 - Ovid Therapeutics Inc. (NASDAQ:OVID) is recognized as a fast-growing penny stock, with analysts recommending it for investment, highlighted by LifeSci Capital initiating coverage with an Outperform rating and a price target of $4 [1] - The company announced successful Phase 1 results for OV350, the first direct activator of the KCC2 transporter tested in humans, achieving primary objectives with a favorable safety profile and no serious adverse events [2] - Ovid is shifting focus from OV350 to OV4071, an oral activator that is 20 times more potent, with plans to submit a regulatory application in Q1 2026 and initiate Phase 1/1b clinical trials in Q2 2026 for treating psychoses related to neurodegenerative conditions [3] Group 2 - Ovid Therapeutics is a biopharmaceutical company dedicated to developing medicines for patients with epilepsies and seizure-related neurological disorders in the US [4]

Core Viewpoint - Ovid Therapeutics Inc. announced positive results from its Phase 1 study of OV350, the first KCC2 direct activator tested in humans, which supports the advancement of its portfolio of oral KCC2 direct activators into clinical development [1][2]. Study Design and Key Results - The Phase 1 study was a randomized, placebo-controlled, single-ascending dose trial involving 16 healthy participants, with doses of 50 mg and 100 mg administered via IV infusion [3]. - Key findings indicated that OV350 demonstrated a good safety profile, with no treatment-related laboratory findings or serious adverse events [6][7]. - Pharmacokinetics for OV350 were as predicted, informing future dosing strategies for KCC2 development programs [6][7]. Future Development Plans - Ovid plans to submit a regulatory application for a Phase 1/1b study of OV4071, the first oral KCC2 direct activator, in Q1 2026, with clinical studies expected to begin in Q2 2026 [2][9]. - OV4071 is noted to be twenty-fold more potent than OV350 in pharmacodynamic models, targeting conditions such as psychosis associated with Parkinson's disease and Lewy body dementia [9]. KCC2 Direct Activators Portfolio - Ovid is advancing a portfolio of KCC2 direct activators, with OV4071 being the most advanced candidate, aimed at restoring excitatory/inhibitory balance in the brain [11][12]. - The company is also developing next-generation KCC2 activators from its proprietary library, designed for both oral and injectable formulations [10].

Core Insights - Ovid Therapeutics Inc. has appointed Dr. Petra Kaufmann as Chief Medical Officer to lead clinical, medical, and regulatory strategy for its pipeline of brain disorder therapeutics [1][2][3] - Dr. Kaufmann has extensive experience in developing CNS therapeutics, including leadership roles in biopharmaceutical companies and the National Institutes of Health [2][3] - The company is focused on advancing its next-generation GABA-AT inhibitor, OV329, and a portfolio of KCC2 direct activators for various CNS disorders [4] Company Overview - Ovid Therapeutics is a biopharmaceutical company based in New York, dedicated to developing small molecule medicines for brain conditions with significant unmet needs [4] - The company is advancing a pipeline that includes OV329 for treatment-resistant seizures and other undisclosed indications, as well as additional compounds targeting the KCC2 transporter [4] Leadership and Expertise - Dr. Kaufmann's background includes significant contributions to the development and global approval of Zolgensma, the first gene therapy for spinal muscular atrophy [2][3] - Her expertise in patient-focused trial design and biomarker strategies is expected to enhance Ovid's R&D capabilities [2][3] - The appointment is seen as a strategic move to strengthen the company's research and development organization [3]

Core Insights - Ovid Therapeutics Inc. announced a CEO succession plan with Meg Alexander set to become CEO on January 1, 2026, while Dr. Jeremy M. Levin transitions to Executive Chairman [1][2][3] - The company reported third-quarter financial results and provided updates on its clinical pipeline, highlighting progress in its drug development programs [1][4][11] Leadership Transition - Meg Alexander has been with Ovid since 2021 and has played a key role in developing the company's pipeline and overseeing operations [2] - Dr. Levin expressed confidence in Alexander's leadership and emphasized the importance of continuity during the transition [3] Pipeline and Clinical Updates - Ovid's OV329, a next-generation GABA-aminotransferase inhibitor, is advancing to Phase 2 patient studies following positive Phase 1 results, demonstrating strong inhibitory activity [4][5][8] - The KCC2 direct activator portfolio is progressing, with OV350 expected to report first-in-human data in Q4 2025 and OV4071 anticipated to enter clinical trials in Q2 2026 [5][9][10] Financial Performance - For Q3 2025, Ovid reported total revenue of $132,000, a decrease from $173,000 in Q3 2024 [15] - Research and development expenses were $5.9 million, down from $7.9 million in the same period last year, while general and administrative expenses increased to $6.8 million from $5.5 million [15] - The net loss for Q3 2025 was $12.2 million, compared to a net loss of $14.0 million in Q3 2024, with a basic and diluted net loss per share of $0.17 [15][19] Funding and Financial Strategy - Ovid completed a private placement of up to $175 million, with an initial closing of approximately $81 million, expected to extend its cash runway into the second half of 2028 [5][11] - As of September 30, 2025, Ovid had $25.6 million in cash, cash equivalents, and marketable securities [15][21]

Core Insights - Ovid Therapeutics' shares increased by 39.2% following positive top-line data from an early-stage study of OV329, a next-generation GABA-AT inhibitor aimed at treating rare and drug-resistant epilepsies [1][6] - The therapy's mechanism involves blocking GABA-AT to enhance brain GABA levels, potentially positioning it as a best-in-class treatment for seizures [1][6] Study Details - The phase I study of OV329 included 68 healthy volunteers and assessed safety, tolerability, pharmacokinetics, and pharmacodynamics with doses ranging from 1 to 5 mg [2] - Participants received once-daily oral doses, with comprehensive safety and ophthalmic evaluations conducted throughout the study [2] Efficacy Results - OV329 demonstrated strong GABAergic activity, increasing inhibition by 53% on the abductor pollicis brevis (APB) muscle and 44% on the first dorsal interosseous (FDI) muscle at the 5 mg dose, compared to no significant change with placebo [7] - The therapy also significantly prolonged the cortical silent period (CSP) by up to 13 milliseconds at the 5 mg dose, indicating enhanced neural inhibition [8] Biomarker Analysis - Magnetic resonance spectroscopy (MRS) indicated a 7.13% increase in brain GABA levels after seven days of treatment, while placebo showed negligible change [9] - Exploratory EEG data suggested increased inhibitory brainwave activity, supporting OV329's GABA-enhancing mechanism [9] Safety Profile - The phase I study reported that OV329 had a favorable safety and tolerability profile, with treatment-related adverse events primarily mild to moderate [10] Future Plans - Following the encouraging phase I results, Ovid Therapeutics plans to initiate a phase IIa study of OV329 in adults with drug-resistant focal onset seizures in Q2 2026, with completion expected by mid-2027 [11] - The company aims to further define OV329's anti-convulsant profile through an open-label seizure study [11] Additional Pipeline - Ovid Therapeutics is also developing another investigational candidate, OV350, in a separate early-stage study for brain diseases [12]

Core Viewpoint - Ovid Therapeutics Inc. has announced a private investment in public equity (PIPE) financing expected to generate gross proceeds of up to $175 million, with an initial closing of approximately $81 million to support its operating plan and clinical pipeline through 2028 [1][6]. Financing Details - The PIPE financing is anticipated to close around October 6, 2025, pending customary closing conditions [1]. - New investors participating in the PIPE include Janus Henderson Investors, RA Capital Management, and others, alongside existing investors [2]. - The company is selling 57,722 shares of Series B non-voting convertible preferred stock, Series A warrants for 38,481,325 shares of common stock, and Series B warrants for 28,861,000 shares of common stock [3]. Securities Structure - Each share of Series B Preferred Stock is convertible into 1,000 shares of common stock, subject to stockholder approval and ownership limitations [4]. - Series A and Series B Warrants have an exercise price of $1.40 per share and will be exercisable following stockholder approval [5]. Use of Proceeds - The net proceeds from the PIPE financing will be used for research and development, general corporate expenses, and working capital needs, with expectations to fund operations into 2028 [6]. Company Overview - Ovid Therapeutics is focused on developing small molecule medicines for brain conditions with significant unmet needs, advancing a pipeline that includes OV329 for treatment-resistant seizures and other compounds targeting CNS disorders [10].

Core Insights - Ovid Therapeutics Inc. announced positive topline results from its Phase 1 study of OV329, a next-generation GABA-aminotransferase inhibitor aimed at treating drug-resistant epilepsies, demonstrating a favorable safety and tolerability profile [1][2][6] Trial Design - The Phase 1 trial involved 68 healthy volunteers, with 51 receiving active treatment and 17 receiving placebo, testing doses from 1 mg to 5 mg [3] - Safety, tolerability, pharmacokinetic, and pharmacodynamic activities were assessed, including rigorous ophthalmic evaluations and extensive exploratory biomarker analyses [3][4] Biomarker and Efficacy Results - OV329 showed significant GABAergic inhibition, with a 53% increase in inhibition at the 5 mg dose as measured on the abductor pollicis brevis muscle [8] - The study confirmed OV329's ability to penetrate the brain and engage its target, achieving biological modulation consistent with elevated GABA levels [4][8] - After 7 days of dosing at 5 mg, mean GABA levels increased by 7.13% in the medial parietal lobe compared to 0.24% in placebo [8] Safety and Tolerability - The safety profile of OV329 was favorable, with all treatment-related adverse events reported as mild and transient, and no evidence of ophthalmic or retinal changes observed [6][9] - Extensive ophthalmic tests showed no adverse effects, contrasting with existing treatments like vigabatrin, which can accumulate in the retina [6] Future Development Plans - Ovid plans to advance OV329 into a Phase 2a study for drug-resistant focal onset seizures, expected to start in Q2 2026 [10] - The company is also progressing its KCC2 direct activator portfolio, with several regulatory and clinical milestones anticipated in the next 12 months [10][11]

Core Insights - Several biotech and healthcare stocks experienced significant after-hours gains on October 1, driven by technical momentum and recent clinical updates rather than new disclosures [1] Company Summaries - Zhongchao Inc. (ZCMD) saw a 14.04% increase in after-hours trading, rising to $1.30 from $1.14, despite no new filings or press releases [2] - AbCellera Biologics Inc. (ABCL) rose 11.41% in after-hours trading, closing at $6.64, following an 18.49% gain during the regular session, attributed to recent clinical trial progress [3][4] - Vor Biopharma Inc. (VOR) surged 9.53% in after-hours trading, recovering from a 19.42% drop during the regular session, with no new updates since a recent announcement regarding clinical data presentation [5] - Incannex Healthcare Inc. (IXHL) gained 6.48% in after-hours trading, partially recovering from a 6.94% drop, with the latest update showing positive Phase 2 trial results for PSX-001 [6] - Ovid Therapeutics Inc. (OVID) shares rose 8.03% in after-hours trading, building on a 5.38% gain during the regular session, with recent earnings report indicating a narrower net loss and higher revenue [7] - Bullfrog AI Holdings Inc. (BFRG) advanced 3.44% in after-hours trading, following a 3.57% rise during the regular session, after announcing an expansion of its sales and marketing team [8]

Core Insights - Biotech stocks experienced strong after-hours gains, driven by Pfizer's announcement of U.S. drug price cuts and a $70 billion investment in domestic manufacturing [1] Group 1: Ovid Therapeutics Inc. (OVID) - Ovid Therapeutics saw a 7.69% increase in after-hours trading, reaching $1.40 after a regular session decline of 7.14% to $1.30 [2] - The stock's regular session selloff was marked by elevated trading volume of over 2.93 million shares, significantly above the average of 2.07 million shares [2] - Recent coverage from Lucid Capital initiated a Buy rating with a price target of $5.50, highlighting Ovid's pipeline assets in Phase 1 trials for drug-resistant epilepsies [3] Group 2: NeuroOne Medical Technologies Corp. (NMTC) - NeuroOne Medical Technologies rose 6.98% in after-hours trading to $0.9506 after a modest decline of 1.27% during the regular session [4] - The trading volume was relatively light at 134,720 shares, below the average of 315,000 shares [4] - The company announced a virtual roadshow webinar scheduled for October 7 to discuss operations and recent FDA clearance [5] Group 3: PepGen Inc. (PEPG) - PepGen experienced a 3.03% rise in after-hours trading, reaching $4.76 after closing at $4.62 [6] - The stock has surged over 120% in the past week due to positive clinical and financial updates [6] - A recent $100 million public offering was completed, expected to support the development of PGN-EDODM1 and PGN-EDO51 [9] Group 4: Reviva Pharmaceuticals Holdings Inc. (RVPH) - Reviva Pharmaceuticals rose 5.81% in after-hours trading to $0.3900 after a 19.56% surge during the regular session [10] - The trading volume was significantly elevated at over 26 million shares, well above the average of 3.9 million shares [10] - The company recently announced a $9 million public offering priced at $0.30 per share [11] Group 5: Anika Therapeutics Inc. (ANIK) - Anika Therapeutics saw a 5.53% increase in after-hours trading, reaching $9.92 after closing at $9.40 [11] - The stock's regular session strength followed a quiet news cycle, with no new filings or press releases [12] - Anika is in focus ahead of its scheduled earnings report on October 30, 2025 [12]